[Hypotensive efficacy of bimatoprost in monotherapy of primary open-angle glaucoma]. / Gipotenzivnaia éffektivnost' bimatoprosta v monoterapii pervichnoi otkrytougol'noi glaukomy.
Vestn Oftalmol
; 134(5. Vyp. 2): 208-214, 2018.
Article
en Ru
| MEDLINE
| ID: mdl-30499519
PURPOSE: To study the effectiveness of monotherapy with bimatoprost in patients with decompensated intraocular pressure (IOP). MATERIAL AND METHODS: 90 patients (132 eyes) with stage I-II glaucoma and decompensated IOP previously treated with timolol, latanoprost and travoprost were included in the study. Average IOP at the beginning of the study was 25.4±2.5 mmHg. All patients had their hypotensive medications substituted by bimatoprost. The patients were examined during the initial appointment, as well as after 4 and 12 weeks. RESULTS: IOP decrease was highest in the group of patients who had been treated with timolol: initially IOP was 26.2±1.8 mmHg, after 4 weeks - 21.0±2.2 mmHg, after 12 weeks - 20.8±1.9 mmHg (p<0.001). The initial IOP of patients who had been treated with latanoprost was 24.8±2.9 mmHg, 21.8±2.4 mmHg after 4 weeks, and 21.6±2.3 mmHg after 12 weeks (p<0.001). Patients who had been treated with travoprost had 25.6±2.2 mmHg initially, 23.0±2.5 mmHg after 4 weeks, and 23.2±2.6 mmHg after 12 weeks (p<0.001). By the end of the study IOP has decreased by 5.4, 3.2 and 2.4 mmHg in the groups of patients who had been treated with timolol, latanoprost and travoprost, respectively. CONCLUSION: Bimatoprost can be used as monotherapy if another hypotensive drug in monotherapy is insufficient for IOP compensation.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Glaucoma de Ángulo Abierto
/
Bimatoprost
/
Antihipertensivos
Límite:
Humans
Idioma:
Ru
Revista:
Vestn Oftalmol
Año:
2018
Tipo del documento:
Article
Pais de publicación:
Rusia